Company Revenue

The company grew more than 60% in the first quarter of 2022 as it continues expanding its portfolio and geographic...

The company declined in the mid-teens in 1Q22 as it exited unprofitable geographies and optimized its portfolio for longer term...

The company grew less than 1% in the first quarter of 2022 as macro environment pressures disrupted both January and...

The company grew in the high single digits for 1Q22 as elective procedures returned to key markets in the second...

The company grew around 1% in 1Q22 on the strength of new product introductions and international stocking orders....

The company grew in the low single digits for 1Q22 as a strong recovery in elective procedures offset other headwinds....

The company grew in the low single digits for the first quarter and expects the orthopedic market's recovery to accelerate...

The company grew in the mid-single digits for 1Q22 as procedure recovery fueled growth. However, supply chain pressures offset some...

The company grew in the low single digits for 1Q22, driven in part by knee replacement and hip replacement gains...

The company grew over +28% in 2021, driven in part by synergies from recently acquired Bioness and Misonix....